Table 2.
Comparison of clinicopathologic characteristics of patients with TNBC achieving pCR/RCB I or RCD II/III after NAC whose peripheral blood was analyzed by liquid CyTOF.
| pCR/RCB I (n = 7) | RCB II/III (n = 7) | |
|---|---|---|
| Age (median, range) | 46 (37–66) | 50 (32–57) |
| Grade at consent (n) | ||
| 2 | 1 | 1 |
| 3 | 5 | 6 |
| Unknown | 1 | 0 |
| Stage at consent (n) | ||
| IA | 2 | 1 |
| IIA | 4 | 3 |
| IIB | 1 | 1 |
| IIIA | 0 | 1 |
| IIIB | 0 | 1 |
| Nodes (n) | ||
| Positive | 2 | 2 |
| Negative | 5 | 5 |
| Pre-NAC tumor size (mm) | ||
| Median | 38 | 25 |
| Range | 21–64 | 8–50 |
| Chemotherapy (n) | ||
| Anthracycline–ccyclophosphamide | 6 | 7 |
| Platinum | 5 | 1 |
| Taxane | 5 | 7 |